Showing results (71-80 of 155) with videos related to

Sort By:
Pageof 16
Blood Advances|October 31, 2025
Decitabine-cedazuridine in patients with MDS and TP53 mutationsSamuel Urrutia, Koji Sasaki, Alex Bataller, et al.
Haematologica|October 30, 2016
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosisJohn O Mascarenhas, Moshe Talpaz, Vikas Gupta, et al.
Leukemia Research|January 9, 2018
Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemiaStephen A Strickland, Aaron C Shaver, Michael Byrne, et al.
Cancer Discovery|September 7, 2018
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous LeukemiaHaley E Ramsey, Melissa A Fischer, Taekyu Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDSMichael R Savona, Daniel A Pollyea, Wendy Stock, et al.
Nature Cancer|April 22, 2021
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cellsBrett M Stevens, Courtney L Jones, Daniel A Pollyea, et al.
The Journal of Molecular Diagnostics : JMD|April 8, 2024
Cost-Effective and Scalable Clonal Hematopoiesis Assay Provides Insight into Clonal DynamicsTaralynn Mack, Caitlyn Vlasschaert, Kelly von Beck, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Cost-effective and scalable clonal hematopoiesis assay provides insight into clonal dynamicsTaralynn Mack, Caitlyn Vlasschaert, Kelly von Beck, et al.
Blood|April 15, 2020
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover studyGuillermo Garcia-Manero, Elizabeth A Griffiths, David P Steensma, et al.
The Lancet. Oncology|February 25, 2018
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human studyHoward A Burris, Ian W Flinn, Manish R Patel, et al.
Pageof 16